227 related articles for article (PubMed ID: 10747801)
1. Conservative mutations of glutamine-125 in herpes simplex virus type 1 thymidine kinase result in a ganciclovir kinase with minimal deoxypyrimidine kinase activities.
Hinds TA; Compadre C; Hurlburt BK; Drake RR
Biochemistry; 2000 Apr; 39(14):4105-11. PubMed ID: 10747801
[TBL] [Abstract][Full Text] [Related]
2. Differential ganciclovir-mediated cell killing by glutamine 125 mutants of herpes simplex virus type 1 thymidine kinase.
Drake RR; Wilbert TN; Hinds TA; Gilbert KM
J Biol Chem; 1999 Dec; 274(52):37186-92. PubMed ID: 10601281
[TBL] [Abstract][Full Text] [Related]
3. Mutation of herpesvirus thymidine kinase to generate ganciclovir-specific kinases for use in cancer gene therapies.
Mercer KE; Ahn CE; Coke A; Compadre CM; Drake RR
Protein Eng; 2002 Nov; 15(11):903-11. PubMed ID: 12538910
[TBL] [Abstract][Full Text] [Related]
4. The A167Y mutation converts the herpes simplex virus type 1 thymidine kinase into a guanosine analogue kinase.
Balzarini J; Liekens S; Esnouf R; De Clercq E
Biochemistry; 2002 May; 41(20):6517-24. PubMed ID: 12009916
[TBL] [Abstract][Full Text] [Related]
5. Mutation of Gln125 to Asn selectively abolishes the thymidylate kinase activity of herpes simplex virus type 1 thymidine kinase.
Degrève B; Esnouf R; De Clercq E; Balzarini J
Mol Pharmacol; 2001 Feb; 59(2):285-93. PubMed ID: 11160865
[TBL] [Abstract][Full Text] [Related]
6. Characterization of herpes simplex virus type 1 thymidine kinase mutants engineered for improved ganciclovir or acyclovir activity.
Kokoris MS; Black ME
Protein Sci; 2002 Sep; 11(9):2267-72. PubMed ID: 12192082
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant.
Kokoris MS; Sabo P; Adman ET; Black ME
Gene Ther; 1999 Aug; 6(8):1415-26. PubMed ID: 10467366
[TBL] [Abstract][Full Text] [Related]
8. Selective abolishment of pyrimidine nucleoside kinase activity of herpes simplex virus type 1 thymidine kinase by mutation of alanine-167 to tyrosine.
Degrève B; Esnouf R; De Clercq E; Balzarini J
Mol Pharmacol; 2000 Dec; 58(6):1326-32. PubMed ID: 11093770
[TBL] [Abstract][Full Text] [Related]
9. A designed equine herpes thymidine kinase (EHV4 TK) variant improves ganciclovir-induced cell-killing.
McSorley T; Ort S; Monnerjahn C; Konrad M
Biochem Pharmacol; 2014 Feb; 87(3):435-44. PubMed ID: 24316433
[TBL] [Abstract][Full Text] [Related]
10. The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to the herpes simplex virus type 1 thymidine kinase.
Gustafson EA; Chillemi AC; Sage DR; Fingeroth JD
Antimicrob Agents Chemother; 1998 Nov; 42(11):2923-31. PubMed ID: 9797227
[TBL] [Abstract][Full Text] [Related]
11. Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing.
Black ME; Kokoris MS; Sabo P
Cancer Res; 2001 Apr; 61(7):3022-6. PubMed ID: 11306482
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxicity and accumulation of ganciclovir triphosphate in bystander cells cocultured with herpes simplex virus type 1 thymidine kinase-expressing human glioblastoma cells.
Rubsam LZ; Boucher PD; Murphy PJ; KuKuruga M; Shewach DS
Cancer Res; 1999 Feb; 59(3):669-75. PubMed ID: 9973216
[TBL] [Abstract][Full Text] [Related]
13. [Herpes simplex virus type 1 thymidine kinase/ganciclovir (HSV(1)-TK/GCV) system as an effective "in vivo death switch" of live tumor vaccines].
Kang Y; Xu CJ; Liu XS; Wu CQ; Zhong CP; Gu JR
Ai Zheng; 2005 Aug; 24(8):909-14. PubMed ID: 16086864
[TBL] [Abstract][Full Text] [Related]
14. Effect of herpes simplex virus thymidine kinase expression levels on ganciclovir-mediated cytotoxicity and the "bystander effect".
Chen CY; Chang YN; Ryan P; Linscott M; McGarrity GJ; Chiang YL
Hum Gene Ther; 1995 Nov; 6(11):1467-76. PubMed ID: 8573619
[TBL] [Abstract][Full Text] [Related]
15. Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing.
Wiewrodt R; Amin K; Kiefer M; Jovanovic VP; Kapoor V; Force S; Chang M; Lanuti M; Black ME; Kaiser LR; Albelda SM
Cancer Gene Ther; 2003 May; 10(5):353-64. PubMed ID: 12719705
[TBL] [Abstract][Full Text] [Related]
16. Kinetics and crystal structure of the wild-type and the engineered Y101F mutant of Herpes simplex virus type 1 thymidine kinase interacting with (North)-methanocarba-thymidine.
Prota A; Vogt J; Pilger B; Perozzo R; Wurth C; Marquez VE; Russ P; Schulz GE; Folkers G; Scapozza L
Biochemistry; 2000 Aug; 39(31):9597-603. PubMed ID: 10924157
[TBL] [Abstract][Full Text] [Related]
17. Synergistic enhancement of herpes simplex virus thymidine kinase/ganciclovir-mediated cytoxicity by hydroxyurea.
Boucher PD; Ostruszka LJ; Shewach DS
Cancer Res; 2000 Mar; 60(6):1631-6. PubMed ID: 10749133
[TBL] [Abstract][Full Text] [Related]
18. Polyamine biosynthesis inhibition enhances HSV-1 thymidine kinase/ganciclovir-mediated cytotoxicity in tumor cells.
Pasanen T; Karppinen A; Alhonen L; Jänne J; Wahlfors J
Int J Cancer; 2003 Apr; 104(3):380-8. PubMed ID: 12569563
[TBL] [Abstract][Full Text] [Related]
19. Superior cytostatic activity of the ganciclovir elaidic acid ester due to the prolonged intracellular retention of ganciclovir anabolites in herpes simplex virus type 1 thymidine kinase gene-transfected tumor cells.
Balzarini J; Degrève B; Andrei G; Neyts J; Sandvold M; Myhren F; de Clercq E
Gene Ther; 1998 Mar; 5(3):419-26. PubMed ID: 9614564
[TBL] [Abstract][Full Text] [Related]
20. Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy.
Black ME; Newcomb TG; Wilson HM; Loeb LA
Proc Natl Acad Sci U S A; 1996 Apr; 93(8):3525-9. PubMed ID: 8622970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
